# Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma

> **NCT03111992** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 26 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** PDR001
- **DRUG:** CJM112
- **DRUG:** LCL161

## Key facts

- **NCT ID:** NCT03111992
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-18
- **Primary completion:** 2020-03-02
- **Final completion:** 2020-03-02
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2022-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03111992

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03111992, "Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03111992. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*